Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Shattuck Labs, Inc.NASDAQ: STTK

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.42M rose 40.3% year over year, ahead of the -12.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 50.4% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.

Context

  • Stock-based compensation amounted to 699.5% of revenue in FY2025, up 532.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +40.3% holds above the trailing-twelve-month pace of -12.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.42M+50.4% QoQ
Last fiscal yearDec 2025
$7M-26.7% YoY
LTMMar 2026
$7.69M-12.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.3%——
1 year-26.7%——
3-year CAGR+2.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7M USD
Year-over-year change
-26.7%
4-year CAGR
+6.4%

Stock-Based Compensation vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.5% is the 5th highest of 10, against a peer median of -13.7%.
  • Stock-based compensation amounts to 768.9% of revenue for STTK, versus a peer median of 12.3%.
STTK Competitors
Stock-Based Compensation for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$1.79B USD-27809.6%+824.6%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥26.02M CNY+1.1%-74.4%—
FTHFaeth Therapeutics, Inc.LTM Jun 2026$17.93M USD+869.7%-39.7%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$16.18M USD+309.7%+51.1%136.2%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$6.81M USD-13.7%-16.3%3.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$6.38M USD-39.9%-18.4%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M USD+122.7%+4.3%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$1.19M USD-32.6%-22.8%—
Peer median (excluding STTK) —-13.7%-16.3%12.3%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
Deferred Income Tax3.04M0000
Stock-Based Compensation5.47M6.46M6.94M9.55M7M
Change in Working Capital(23.55M)(4.46M)(4.1M)3.02M(785K)
Accounts Receivables00000
Inventory00000
Accounts Payables7.87M(2.84M)(5.63M)832K(318K)
Other Working Capital(31.41M)(1.62M)1.53M2.19M(467K)
Other Non-Cash Items1.52M2.38M(816K)(1.5M)(971K)
Operating Cash Flow(57.12M)(94.5M)(81.23M)(60.52M)(39.88M)
Capital Expenditures(7.93M)(11.61M)(407K)(59K)(71K)
Acquisitions (Net)2.52M104K000
Purchases of Investments(204.09M)(132.38M)(79.73M)(93.55M)(43.42M)
Sales of Investments201.58M193.33M191M85.1M35.6M
Other Investing Activities(2.52M)0000
Investing Cash Flow(10.44M)49.44M110.86M(8.51M)(7.89M)
Debt Repayment00000
Common Stock Issued1.93M171K48.67M(17K)44.48M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(53K)804K(65K)
Financing Cash Flow1.93M171K48.62M787K44.57M
Effect of Forex Changes00000
Net Change in Cash(65.63M)(44.89M)78.25M(68.24M)(3.2M)
Free Cash Flow(65.04M)(106.11M)(81.64M)(60.57M)(39.95M)

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.